Skip to Main Content

Paper Details

VRK1 as a synthetic lethal target in VRK2 promoter-methylated cancers of the nervous system.
JCI Insight
10
2022
CRISPR, Cas9, RNA, VRK1, VRK2, VRK2 promoter, adult and pediatric gliomas, barrier-to-autointegration factor, cancer, cancer cell lines, cancer cells, cancers of nervous system, cancers of the nervous system, gliomas, human, neuroblastomas, paralog, vaccinia-related kinase 1
Author NameAffiliation
Bernhard EnglingerBroad Institute of MIT and Harvard
Bernhard EnglingerComprehensive Cancer Center, Medical University of Vienna
Bernhard EnglingerDana-Farber/Boston Children's Cancer and Blood Disorder Center and Harvard Medical School
Maria TrissalBroad Institute of MIT and Harvard
Maria TrissalDana-Farber/Boston Children's Cancer and Blood Disorder Center and Harvard Medical School
Eshini PanditharatnaBroad Institute of MIT and Harvard
Eshini PanditharatnaDana-Farber/Boston Children's Cancer and Blood Disorder Center and Harvard Medical School
Rameen BeroukhimDana-Farber Cancer Institute, Harvard Medical School
Rameen BeroukhimBroad Institute of MIT and Harvard
Keith L LigonBroad Institute of MIT and Harvard
Keith L Ligon
Keith L LigonComprehensive Cancer Center, Medical University of Vienna
Kimberly StegmaierBroad Institute of MIT and Harvard
Kimberly StegmaierDana-Farber/Boston Children's Cancer and Blood Disorder Center and Harvard Medical School
Kimberly StegmaierBroad Institute of MIT and Harvard
Kimberly StegmaierDana-Farber/Boston Children's Cancer and Blood Disorder Center and Harvard Medical School
Mariella G FilbinBroad Institute of MIT and Harvard
Mariella G FilbinDana-Farber/Boston Children's Cancer and Blood Disorder Center and Harvard Medical School
William C HahnDana-Farber Cancer Institute, Harvard Medical School
William C HahnBroad Institute of MIT and Harvard
William C HahnDana-Farber Cancer Institute, Harvard Medical School
William C HahnBroad Institute of MIT and Harvard
  • 1 - 22

Datasets

Release 1.2